BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
BIOMEDICA free soluble RANKL ELISA - References/Publications
free sRANKL High Sensitivity ELISA REFERENCES published after 2015, using assay #BI-20462
1. Substrate Microarchitecture Shapes the Paracrine Crosstalk of Stem Cells with Endothelial Cells and Osteoblasts Francisco Martín-Saavedra, Lara Crespo, Clara Escudero-Duch, Laura Saldaña, Enrique Gómez-Barrena, and Nuria Vilaboa Sci Rep. 2017; 7: 15182. PMCID: PMC5680323
2. Paracrine interactions between mesenchymal stem cells and macrophages are regulated by 1,25-dihydroxyvitamin D3 Laura Saldaña, Gema Vallés, Fátima Bensiamar, Francisco José Mancebo, Eduardo García-Rey, and Nuria Vilaboa Sci Rep. 2017; 7: 14618. PMCID: PMC5668416
3. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer Stefan Kiechl, Daniel Schramek, Martin Widschwendter, Evangelia-Ourania Fourkala, Alexey Zaikin, Allison Jones, Bernadette Jaeger, Brigitte Rack, Wolfgang Janni, Christoph Scholz, Johann Willeit, Siegfried Weger, Agnes Mayr, Andrew Teschendorff, Adam Rosenthal, Lindsay Fraser, Susan Philpott, Louis Dubeau, Mohammed Keshtgar, Rebecca Roylance, Ian J. Jacobs, Usha Menon, Georg Schett, Josef M. Penninger Oncotarget, 2017, 3811-3825. PMID: 28002811
4. Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients Uwe Lange, Katharina Classen, Ulf Müller-Ladner, Manfred Richter Clinical Transplantation, 2017. PMID: 28940569
5. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial Max Norman Tandrup Lambert, Catrine Bundgaard Thybo, Simon Lykkeboe, Lars Melholt Rasmussen, Xavier Frette, Lars Porskjær Christensen, Per Bendix Jeppesen The American Journal of Clinical Nutrition, 2017, 909-920. PMID: 28768651
6. Association of Circulating Osteoprotegerin (OPG) and RANKL with Intracranial Arterial Calcification in Hypertensive Patients. Cheng Y., Wang Y. , Guo Q. , Zhu D. , Li Y. Journal of Hypertension, 2017.
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 1/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
7. Effects of short-term dry immersion on bone remodeling markers, insulin and adipokines Marie-Thérèse Linossier , Liubov E. Amirova, Mireille Thomas, Myriam Normand, Marie-Pierre Bareille, Guillemette Gauquelin-Koch, Arnaud Beck, Marie-Claude Costes-Salon, Christine Bonneau, Claude Gharib, Marc-Antoine Custaud, Laurence Vico PLOS One, 2017. PMID: 28806419
8. Serum irisin and myostatin levels after 2 weeks of high-altitude climbing Ewa Śliwicka, Tomasz Cisoń, Zbigniew Kasprzak, Alicja Nowak, and Łucja Pilaczyńska-Szcześniak PLoS One. 2017; 12(7): e0181259. PMCID: PMC5521782
9. Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis Inês Pedro Perpétuo, Joana Caetano-Lopes, Ana Maria Rodrigues, Raquel Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João Eurico Fonseca RMD Open. 2017; 3(1): e000365. PMCID: PMC5604603
10. Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort Danja Sarink, Helena Schock, Theron Johnson, Kim Overvad, Marianne Holm, Anne Tjønneland, Marie-Christine Boutron-Ruault, Mathilde His, Marina Kvaskoff, Heiner Boeing, Pagona Lagiou, Eleni-Maria Papatesta, Antonia Trichopoulou, Domenico Palli, Valeria Pala, Amalia Mattiello, Rosario Tumino, Carlotta Sacerdote, H.B(as) Bueno-de-Mesquita, Carla H van Gils, Petra H Peeters, Elisabete Weiderpass, Antonio Agudo, Maria-José Sánchez, Maria-Dolores Chirlaque, Eva Ardanaz, Pilar Amiano, Kay Tee Khaw, Ruth Travis, Laure Dossus, Mark Gunter, Sabina Rinaldi, Melissa Merritt,16 Elio Riboli,16 Rudolf Kaaks,1 and Renée T. Fortner Cancer Prev Res (Phila). 2017 Sep; 10(9): 525–534. PMCID: PMC5603271
11. Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study Barbara Hauser, Sizheng Zhao, Micaela R. Visconti, Philip L. Riches, William D. Fraser, Isabelle Piec, Nicola J. Goodson, and Stuart H. Ralston Calcif Tissue Int. 2017; 101(4): 375–383. PMCID: PMC5587630
12. Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults Inger Hee Mathiesen, Mohammad Salem, Jan Gerstoft, Julie Christine Gaardbo, Niels Obel, Court Pedersen, Henrik Ullum, Susanne Dam Nielsen, and Ann-Brit Eg Hansen BMC Infect Dis. 2017; 17: 262. PMCID: PMC5387326
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 2/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
13. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development Bożena Bruhn-Olszewska, Anna Korzon-Burakowska, Grzegorz Węgrzyn, and Joanna Jakóbkiewicz-Banecka Sci Rep. 2017; 7: 501. PMCID: PMC5428699
14. Markers of bone metabolism during 14 days of bed rest in young and older men J. Buehlmeier, P. Frings-Meuthen, N. Mohorko, P. Lau, S. Mazzucco, J.L. Ferretti, G. Biolo, R. Pisot, B. Simunic, and J. Rittweger J Musculoskelet Neuronal Interact. 2017 Mar; 17(1): 399–408. PMCID: PMC538376
15. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis Inês P. Perpétuo, Joana Caetano-Lopes, Ana Maria Rodrigues, Raquel Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João E. Fonseca Biomed Res Int. 2017; 2017: 2690402. PMCID: PMC5327780
16. Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in Circulating Osteoclast Precursors Inês P. Perpétuo, Joana Caetano-Lopes, Elsa Vieira-Sousa, Raquel Campanilho- Marques, Cristina Ponte, Nikita Khmelinskii, Helena Canhão, Mari Ainola, and João E. Fonseca Front Med (Lausanne). 2017; 4: 5. PMCID: PMC5269449
17. NOTCH1 Mutations in Aortic Stenosis: Association with Osteoprotegerin/RANK/RANKL Olga Irtyuga, Anna Malashicheva, Ekaterina Zhiduleva, Olga Freylikhman, Oxana Rotar, Magnus Bäck, Svetlana Tarnovskaya, Anna Kostareva, and Olga Moiseeva Biomed Res Int. 2017; 2017: 6917907. PMCID: PMC5299165
18. Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis Carmen Gómez-Vaquero, Irene Martín, Estibaliz Loza, Loreto Carmona, José Ivorra, José Antonio Narváez, Javier Hernández-Gañán, Pedro Alía, and Javier Narváez PLoS One. 2016; 11(12): e0166691. PMCID: PMC5135438
19. HAJDU CHENEY SYNDROME; REPORT OF A NOVEL NOTCH2 MUTATION AND TREATMENT WITH DENOSUMAB Adami Giovanni, Rossini Maurizio, Gatti Davide, Orsolini Giovanni, Idolazzi Luca, Viapiana Ombretta, Scarpa Aldo, and Canalis Ernesto Bone. 2016 Nov; 92: 150–156. PMCID: PMC5056853
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 3/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
20. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease Ludmila Ugay, Evgenia Kochetkova, Vera Nevzorova, and Yuliya Maistrovskaia Chin Med J (Engl). 2016 Jul 20; 129(14): 1696–1703. PMCID: PMC4960959
21. THU0477 Effect of Recent Spinal Cord Injury on the OPG/RANKL System and Its Relationship with Bone Loss and Antiosteoporotic Response To Denosumab Therapy. Preliminary Results L. Gifre, J. Vidal, S. Ruiz-Gaspà, E. Portell, A. Monegal, A. Muxi, N. Guañabens, P. Peris Annals of the Rheumatic Diseases, 06.2016. PMID: 28580511
22. THU0476 Efficacy of Denosumab for The Treatment of Osteoporosis in Japanese Patients with Rheumatoid Arthritis K. Oh, O. Namiki, Y. Toyoshima, K. Inagaki, K. Kanbe, J. Chiba Annals of the Rheumatic Diseases, 06.2016. PMID: 26585988
23. Path Analysis Identifies Receptor Activator of Nuclear Factor-B Ligand, Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone Erosion Relationship in Gout Ashika Chhana, Opetaia Aati, Gregory D. Gamble, Karen E. Callon, Anthony J. Doyle, Mark Roger, Fiona M. McQueen, Anne Horne, Ian R. Reid, Jillian Cornish, and Nicola Dalbeth J Rheumatol, Feb 2016; 43: 445 - 449.
24. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis Sara Remuzgo-Martínez, Fernanda Genre, Raquel López-Mejías, Begoña Ubilla, Verónica Mijares, Trinitario Pina, Alfonso Corrales, Ricardo Blanco, Javier Martín, Javier Llorca, and Miguel A. González-Gaya Sci Rep. 2016; 6: 29713. PMCID: PMC4940734
25. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study Helena Schock, Anne Zeleniuch-Jacquotte, Eva Lundin, Kjell Grankvist, Hans-Åke Lakso, Annika Idahl, Matti Lehtinen, Heljä-Marja Surcel, and Renée T. Fortner BMC Pregnancy Childbirth. 2016; 16: 146. PMCID: PMC4932669
26. Toward improved phosphorus efficiency in monogastrics—interplay of serum, minerals, bone, and immune system after divergent dietary phosphorus supply in swine Michael Oster, Franziska Just, Kirsten Büsing, Petra Wolf, Christian Polley, Brigitte Vollmar, Eduard Muráni, Siriluck Ponsuksili, and Klaus Wimmers Am J Physiol Regul Integr Comp Physiol. 2016 May 15; 310(10): R917–R925. PMCID: PMC4896080
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 4/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
27. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P. Osteoporos Int. 2015 Oct;26(10):2521-7. PMID: 25990355
28. Notch Signaling Induces Root Resorption via RANKL and IL-6 from hPDL Cells J. Kikuta, M. Yamaguchi, M. Shimizu, T. Yoshino, and K. Kasai Journal of Dental Research, Jan 2015; 94: 140-147. PMID: 25376720
free sRANKL ELISA REFERENCES published before 2015, using assays #BI-20422H, #BI-20452
29. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A Daniela Melchiorre, Silvia Linari, Mirko Manetti, Eloisa Romano, Francesco Sofi, Marco Matucci-Cerinic, Christian Carulli, Massimo Innocenti, Lidia Ibba-Manneschi, and Giancarlo Castaman Haematologica, Feb 2016; 101: 219 - 225. PMCID: PMC4938330
30. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis Inês P. Perpétuo, Rita Raposeiro, Joana Caetano-Lopes, Elsa Vieira-Sousa, Raquel Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João E. Fonseca PLoS One. 2015; 10(12): e0144655. PMCID: PMC4682624
31. Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis Katharina Kurz, Manfred Herold, Elisabeth Russe, Werner Klotz, Guenter Weiss, and Dietmar Fuchs Dis Markers. 2015; 2015: 276969. PMCID: PMC4631883
32. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study Eva Kulcsar-Jakab, Zsofia Petho, Zoltan Pap, Edit Kalina, Roza Foldesi, Adam Balogh, Peter Antal-Szalmas, and Harjit Pal Bhattoa BMC Musculoskelet Disord. 2015; 16: 227. PMCID: PMC4551745
33. Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts Maria Rita Pitari, Marco Rossi, Nicola Amodio, Cirino Botta, Eugenio Morelli, Cinzia Federico, Annamaria Gullà, Daniele Caracciolo, Maria Teresa Di Martino, Mariamena Arbitrio, Antonio Giordano, Pierosandro Tagliaferri, and Pierfrancesco Tassone Oncotarget. 2015 Sep 29; 6(29): 27343–27358. PMCID: PMC4694994
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 5/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
34. Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging E Kastritis, M Gavriatopoulou, M A Dimopoulos, E Eleutherakis-Papaiakovou, N Kanellias, M Roussou, C Pamboucas, S T Toumanidis, and E Terpos Blood Cancer J. 2015 Jun; 5(6): e319. PMCID: PMC4648482
35. Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion Stéphanie A Demoulin, Joan Somja, Anaëlle Duray, Samuel Guénin, Patrick Roncarati, Philippe O Delvenne, Michael F Herfs, and Pascale M Hubert Oncoimmunology. 2015 Jun; 4(6): e1008334. PMCID: PMC4485731
36. Topographical cues regulate the crosstalk between MSCs and macrophages Gema Vallés, Fátima Bensiamar, Lara Crespo, Manuel Arruebo, Nuria Vilaboa, and Laura Saldañaa Biomaterials. 2015 Jan; 37: 124–133. PMCID: PMC4245715
37. Denosumab for the prevention of skeletal complications in metastatic castration- resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events M. R. Smith, R. E. Coleman, L. Klotz, K. Pittman, P. Milecki, S. Ng, K. N. Chi, A. Balakumaran, R. Wei, H. Wang, A. Braun, and K. Fizazi Ann Oncol. 2015 Feb;26(2):368-374. PMID: 25425475
38. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels Eugènia Negredo, Adolfo Diez-Pérez, Anna Bonjoch, Pere Domingo, Núria Pérez- Álvarez, Mar Gutierrez, Gracia Mateo, Jordi Puig, Patricia Echeverría, Roser Escrig, and Bonaventura Clotet J. Antimicrob. Chemother., 2015; 70: 2104-2107 PMID: 25769303
39. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion Shin-ya Kawashiri, Takahisa Suzuki, Yoshikazu Nakashima, Yoshiro Horai, Akitomo Okada, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Kazuhiko Arima, Hideki Nakamura, Tomoki Origuchi, Masataka Uetani, Kiyoshi Aoyagi, Katsumi Eguchi, and Atsushi Kawakami Rheumatology, Mar 2014; 53: 562-569. PMID: 24319104
40. Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use Mie Jin Lim, Seong Ryul Kwon, Kowoon Joo, Min Jung Son, Shin-Goo Park, and Won Park Korean J Intern Med. 2014 Nov; 29(6): 807–813. PMCID: PMC4219971
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 6/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
41. Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis Kristyna Brabnikova-Maresova, Katerina Jarosova, Karel Pavelka, and Jan J Stepan Arthritis Res Ther. 2014; 16(5): 460. PMCID: PMC4236454
42. Bone mineral status in Egyptian children with classic congenital adrenal hyperplasia. A single-center study from Upper Egypt Kotb Abbass Metwalley and Abdel-Rahman Abbdel-Hamed El-Saied Indian J Endocrinol Metab. 2014 Sep-Oct; 18(5): 700–704. PMCID: PMC4171895
43. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5 Osteoporos Int. 2014 Oct; 25(10): 2383–2388. PMCID: PMC4659359
44. Osteoclastogenic Potential of Peripheral Blood Mononuclear Cells in Cleidocranial Dysplasia Maria Felicia Faienza, Annamaria Ventura, Laura Piacente, Maria Ciccarelli, Margherita Gigante, Loreto Gesualdo, Silvia Colucci, Luciano Cavallo, Maria Grano, and Giacomina Brunetti Int J Med Sci. 2014; 11(4): 356–364. PMCID: PMC3936030
45. Relationship between Biochemical Bone Markers and Bone Mineral Density in Patients with Phenylketonuria under Restricted Diet Hala M. Koura, Sherif M. Zaki, Nagwa A. Ismail, Emad E. Salama, Dalia H. El Lebedy, and Laila K. Effat Iran J Pediatr. 2014 Feb; 24(1): 23–28. PMCID: PMC4359600
46. Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. Patrick H. Dessein, Raquel López-Mejias, Carlos González-Juanatey, Fernanda Genre, José A. Miranda-Filloy, Javier Llorca, and Miguel A. González-Gay J Rheumatol, Mar 2014; 41: 429-436. PMID: 24488413
47. Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate Shankar Revu, Petra Neregård, Erik af Klint, Marina Korotkova, and Anca Irinel Catrina Arthritis Res Ther. 2013; 15(6): R205. PMCID: PMC3978873
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 7/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
48. OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study Andrea Z. LaCroix, Rebecca D. Jackson, Aaron Aragaki, Charles Kooperberg, Jane A. Cauley, Zhao Chen, Meryl S. LeBoff, David Duggan, and Jean Wactawski- Wendeg Bone. 2013 Oct; 56(2): 10.1016/j.bone.2013.05.018. PMCID: PMC3832355
49. Juvenile Paget’s Disease In An Iranian Kindred With Vitamin D Deficiency And Novel Homozygous TNFRSF11B Mutation Forough Saki, Zohreh Karamizadeh, Shiva Nasirabadi, Steven Mumm, William H. McAlister, and Michael P. Whyte J Bone Miner Res. 2013 Jun; 28(6): 1501–1508. PMID: PMC3663917
50. Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL Gaëlle Picarda, Etienne Matous, Jérôme Amiaud, Céline Charrier, François Lamoureux, Marie-Françoise Heymann, Franck Tirode, Bruno Pitard, Valérie Trichet, Dominique Heymann, and Françoise Redini J Bone Oncol. 2013 Sep; 2(3): 95–104. PMCID: PMC4723385
51. Human Apolipoprotein E Isoforms differentially affect Bone Mass and Turnover in vivo Marco Dieckmann, F. Timo Beil, Brigitte Mueller, Alexander Bartelt, Robert P. Marshall, Till Koehne, Michael Amling, Wolfgang Ruether, Jackie A. Cooper,6 Steve E. Humphries, Joachim Herz, and Andreas Niemeier J Bone Miner Res. 2013 Feb; 28(2): 236–245. PMCID: PMC3547162
52. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density Maira L Mendonça, Francisco A Pereira, Marcello H Nogueira-Barbosa, Lucas M Monsignore, Sara R Teixeira, Plauto CA Watanabe, Lea MZ Maciel, and Francisco JA de Paula BMC Endocr Disord. 2013; 13: 1. PMCID: PMC3546901
53. Traditional and Novel Bone Remodeling Markers in Premenopausal and Postmenopausal Women Sonsoles Botella, Patricia Restituto, Ignacio Monreal, Inmaculada Colina, Amparo Calleja, and Nerea Varo J. Clin. Endocrinol. Metab., Nov 2013; 98: E1740-E1748. PMID: 24001743
54. Activation of the receptor activator of the nuclear factor-B ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures Antonella Galeone, Giacomina Brunetti, Crescenzia Rotunno, Angela Oranger, Silvia Colucci, Luigi de Luca Tupputi Schinosa, Alberta Zallone, Maria Grano, and Domenico Paparella Eur J Cardiothorac Surg, Aug 2013; 44: e141-e147. PMID: 23671202
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 8/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
55. An Independent Positive Relationship Between the Serum Total Osteocalcin Level and Fat-Free Mass in Healthy Premenopausal Women Jian-min Liu, Hong-yan Zhao, Lin Zhao, Ying Chen, Lian-zhen Zhang, Bei Tao, Li- hao Sun, Yong-ju Zhao, Wei-qing Wang, Man-yin Xu, Jia-lun Chen, and Guang Ning J. Clin. Endocrinol. Metab., May 2013; 98: 2146-2152. PMID: 23553865
56. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP—a possible mechanism for specific inhibition of radiological destruction Inga-Lill Engvall, Björn Svensson, Annelies Boonen, Désirée van der Heijde, Ulf H. Lerner, Ingiäld Hafström, and on behalf of the BARFOT study group Rheumatology, Apr 2013; 52: 733-742. PMID: 23275387
57. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment Giacomina Brunetti, Maria Felicia Faienza, Laura Piacente, Annamaria Ventura, Angela Oranger, Claudia Carbone, Adriana Di Benedetto, Graziana Colaianni, Margherita Gigante, Giorgio Mori, Loreto Gesualdo, Silvia Colucci, Luciano Cavallo, and Maria Grano Am J Physiol Endocrinol Metab, Mar 2013; 304: E546 - E554. PMID: 23299503
58. Receptor Activator for NF-B Ligand in Acute Myeloid Leukemia: Expression, Function, and Modulation of NK Cell Immunosurveillance Benjamin Joachim Schmiedel, Tina Nuebling, Julia Steinbacher, Alexandra Malinovska, Constantin Maximilian Wende, Miyuki Azuma, Pascal Schneider, Ludger Grosse-Hovest, and Helmut Rainer Salih J. Immunol., Jan 2013; 190: 821 - 831. PMID: 23241893
59. Bone metabolism compensates for the delayed growth in small for gestational age neonates Roxane Tenta, Ifigeneia Bourgiezi, Evangelos Aliferis, Magdalini Papadopoulou, Antonis Gounaris, and Maria Skouroliakou Organogenesis. 2013 Jan 1; 9(1): 55–59. PMCID: PMC3674041
60. Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial Athanasios D. Anastasilakis, Stergios A. Polyzos, Athina Gkiomisi, Ilias Bisbinas, Spyridon Gerou, and Polyzois Makras J. Clin. Endocrinol. Metab., 2013; 98: 3206-3212. PMID: 23788684
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 9/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
61. Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates Masakazu Nagashima, Hiroshi Takahashi, Kenichi Shimane, Yuichi Nagase, and Koichi Wauke Arthritis Res Ther. 2012; 14(5): R224. PMCID: PMC3580535
62. Changes of Serum Soluble Receptor Activator for Nuclear Factor-κB Ligand after Glucocorticoid Therapy Reflect Regulation of Its Expression by Osteoblasts Kaneko K, Kusunoki N, Hasunuma T, Kawai S. The Journal of Clinical Endocrinology and Metabolism. 2012;97(10):E1909-E1917. PMCID: PMC3462941
63. Vertebral fractures in patients with inflammatory bowel disease COMPARED with a healthy population: a prospective case-control study Vázquez MA, Lopez E, Montoya MJ, Giner M, Pérez-Temprano R, Pérez-Cano R. BMC Gastroenterology. 2012;12:47. PMCID: PMC3438096
64. The relationship between osteoclastogenic and anti-osteoclastogenic pro- inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues Zupan J, Komadina R, Marc J. Journal of Biomedical Science. 2012;19(1):28. PMCID: PMC3307025
65. Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma Clive Henry Buckle, Evy De Leenheer, Michelle Anne Lawson, Kwee Yong, Neil Rabin, Mark Perry, Karen Vanderkerken, and Peter Ian Croucher PLoS ONE. 2012;7(8):e41127. PMCID: PMC3430669
66. Changes of Serum Soluble Receptor Activator for Nuclear Factor-B Ligand after Glucocorticoid Therapy Reflect Regulation of Its Expression by Osteoblasts Kaichi Kaneko, Natsuko Kusunoki, Tomoko Hasunuma, and Shinichi Kawai J. Clin. Endocrinol. Metab., Oct 2012; 97: E1909 - E1917. PMCID: PMC3462941
67. Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis Polyzois Makras, Stergios A. Polyzos, Athanasios D. Anastasilakis, Evangelos Terpos, George Kanakis, Marian Schini, Athanasios Papatheodorou, and Gregory A. Kaltsas J. Clin. Endocrinol. Metab., Apr 2012; 97: E618 - E621. PMID: 22278426
68. Diets Higher in Dairy Foods and Dietary Protein Support Bone Health during Diet- and Exercise-Induced Weight Loss in Overweight and Obese Premenopausal Women Andrea R. Josse, Stephanie A. Atkinson, Mark A. Tarnopolsky, and Stuart M. Phillips J. Clin. Endocrinol. Metab., Jan 2012; 97: 251 - 260.
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 10/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
PMID: 22049177
69. First inducible transgene expression in porcine large animal models Nikolai Klymiuk, Wolfgang Böcker, Veronika Schönitzer, Andrea Bähr, Tamara Radic, Thomas Fröhlich, Annegret Wünsch, Barbara Keßler, Mayuko Kurome, Eleonore Schilling, Nadja Herbach, Rüdiger Wanke, Hiroshi Nagashima, Wolf Mutschler, Georg J. Arnold, Reinhard Schwinzer, Matthias Schieker, and Eckhard Wolf FASEB J, Mar 2012; 26: 1086 - 1099. PMID: 22138035
70. Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes Aristeidis Stavroulopoulos, Christine J. Porter, Kate Pointon, John M. Monaghan, Simon D. Roe, and Michael J.D. Cassidy Nephrol. Dial. Transplant., Aug 2011; 26: 2582 - 2589. PMID: 21224493
71. RANKL Is a Downstream Mediator for Insulin-Induced Osteoblastic Differentiation of Vascular Smooth Muscle Cells Ling-Qing Yuan, Jia-Hua Zhu, Hua-Wen Wang, Qiu-Hua Liang, Hui Xie, Xian-Ping Wu, Hua Zhou, Rong-Rong Cui, Zhi-Feng Sheng, Hou-De Zhou, Xiao Zhu, Guan- Ying Liu, You-Shuo Liu, and Er-Yuan Liao PLoS ONE. 2011;6(12):e29037. PMCID: PMC3240644
72. Correlation of Circulating Omentin-1 with Bone Mineral Density in Multiple Sclerosis: The Crosstalk between Bone and Adipose Tissue Majid Assadi, Hooman Salimipour, Samad Akbarzadeh, Reza Nemati, Syed Mojtaba Jafari, Afshar Bargahi, Zahra Samani, Mohammad Seyedabadi, Zahra Sanjdideh, and Iraj Nabipour PLoS ONE. 2011;6(9):e24240. PMCID: PMC3174149
73. The RANKL/RANK/OPG Signaling Pathway Mediates Medial Arterial Calcification in Diabetic Charcot Neuroarthropathy Agbor Ndip, Alfred Williams, Edward B. Jude, Ferdinand Serracino-Inglott, Steve Richardson, J.V. Smyth, Andrew J.M. Boulton, and M. Yvonne Alexander Diabetes, Aug 2011; 60: 2187 - 2196. PMCID: PMC3142088
74. Serum osteoprotegerin levels are related to height loss: The Tromsø Study Jørgensen L, Hansen J-B, Brox J, Mathiesen E, Vik A, Jacobsen BK. European Journal of Epidemiology. 2011;26(4):305-312. PMCID: PMC3088831
75. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus Jong Suk Park, Min Ho Cho, Ji Sun Nam, Jeong Seon Yoo, Chul Woo Ahn, Bong Soo Cha, Kyung Rae Kim, and Hyun Chul Lee Eur. J. Endocrinol., Jan 2011; 164: 69 - 74. PMCID: PMC3000683
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 11/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
76. Circulating osteoprotegerin and soluble receptor activator of nuclear factor B ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction Carmen Emanuela Pepene, Ioana Rada Ilie, Ioan Marian, and Ileana Duncea Eur. J. Endocrinol., Jan 2011; 164: 61 - 68. PMID: 20974706
77. Dissociation of Osteogenic and Immunological Effects by the Selective Glucocorticoid Receptor Agonist, Compound A, in Human Bone Marrow Stromal Cells. Martina Rauner, Claudia Goettsch, Nicola Stein, Sylvia Thiele, Martin Bornhaeuser, Karolien De Bosscher, Guy Haegeman, Jan Tuckermann, and Lorenz C. Hofbauer Endocrinology, Jan 2011; 152: 103 - 112. PMID: 21084452
78. Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing Alessandra Colombini, Giovanni Lombardi, Emanuela Galliera, Giada Dogliotti, Pietro Randelli, Alexander Meerssemann, Giuseppe Mineo, Paolo Cabitza, and Massimiliano Marco Corsi International Orthopaedics. 2011;35(5):777-782. PMCID: PMC3080502
79. Circulating osteoprotegerin and soluble receptor activator of nuclear factor B ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Carmen Emanuela Pepene, Ioana Rada Ilie, Ioan Marian, and Ileana Duncea Eur. J. Endocrinol., Jan 2011; 164: 61 - 68. PMID: 20974706
80. Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children Wasilewska A, Rybi-Szuminska A, Zoch-Zwierz W. Pediatric Nephrology. 2010;25(10):2067-2075. PMCID: PMC2923718
81. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Lilian H D van Tuyl, Alexandre E Voskuyl, Maarten Boers, Piet Geusens, Robert B M Landewé, Ben A C Dijkmans, and Willem F Lems Ann Rheum Dis, Sep 2010; 69: 1623 - 1628. PMID: 20525836
82. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow- derived mesenchymal stromal cells into osteoblasts Hichame Id Boufker, Laurence Lagneaux, Mehdi Najar, Martine Piccart, Ghanem Ghanem, Jean-Jacques Body, and Fabrice Journé BMC Cancer. 2010;10:298. PMCID: PMC3087319
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 12/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
83. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident CVD and mortality Wolfgang Lieb, Philimon Gona, Martin G. Larson, Joseph M Massaro, Izabella Lipinska, John F. Keaney, Jr, Jian Rong, Diane Corey, Udo Hoffmann, Caroline S Fox, Ramachandran S. Vasan, Emelia J. Benjamin, Christopher J O’Donnell, and Sekar Kathiresan Arteriosclerosis, thrombosis, and vascular biology. 2010;30(9):1849-1854. PMCID: PMC3039214
84. Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia Soha M. Abd El Dayem, Ghada M. Anwar, Hassan Salama, Ashraf F. Kamel, and Nahed Emara Archives of Medical Science : AMS. 2010;6(1):104-110. PMCID: PMC3278952
85. No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year Rolf Jorde, Monica Sneve, Peter A Torjesen, Yngve Figenschau, John-Bjarne Hansen, and Guri Grimnes Nutrition Journal. 2010;9:1. PMCID: PMC2818614
86. Genome-Wide Association Meta-Analysis of Cortical Bone Mineral Density Unravels Allelic Heterogeneity at the RANKL Locus and Potential Pleiotropic Effects on Bone Lavinia Paternoster, Mattias Lorentzon, Liesbeth Vandenput, Magnus K. Karlsson, Östen Ljunggren, Andreas Kindmark, Dan Mellstrom, John P. Kemp, Caroline E. Jarett, Jeff M. P. Holly, Adrian Sayers, Beate St. Pourcain, Nicholas J. Timpson, Panos Deloukas, George Davey Smith, Susan M. Ring, David M. Evans, Jon H. Tobias, and Claes Ohlsson PLoS Genetics. 2010;6(11):e1001217. PMCID: PMC2987837
87. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion Nicola Dalbeth, Bregina Pool, Timothy Smith, Karen E Callon, Maria Lobo, William J Taylor, Peter B Jones, Jillian Cornish, and Fiona M McQueen Arthritis Research & Therapy. 2010;12(4):R164. PMCID: PMC2945067
88. Bone Impairment in Phenylketonuria Is Characterized by Circulating Osteoclast Precursors and Activated T Cell Increase Ilaria Roato, Francesco Porta, Alessandro Mussa, Lucia D'Amico, Ludovica Fiore, Davide Garelli, Marco Spada, and Riccardo Ferracini PLoS ONE. 2010;5(11):e14167. PMCID: PMC2994752
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 13/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
89. Biomarkers of the Osteoprotegerin Pathway: Clinical Correlates, Subclinical Disease, Incident Cardiovascular Disease, and Mortality. Wolfgang Lieb, Philimon Gona, Martin G. Larson, Joseph M. Massaro, Izabella Lipinska, John F. Keaney, Jr, Jian Rong, Diane Corey, Udo Hoffmann, Caroline S. Fox, Ramachandran S. Vasan, Emelia J. Benjamin, Christopher J. O'Donnell, and Sekar Kathiresan Arterioscler Thromb Vasc Biol, Sep 2010; 30: 1849 - 1854. PMID: 20448212
90. Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome. Valentina Camozzi, Francesca Sanguin, Nora Albigier, Carla Scaroni, Franco Mantero, Martina Zaninotto, Annachiara Frigo, Michele Piccolo, and Giovanni Luisetto Eur. J. Endocrinol., Jan 2010; 162: 85 - 90. PMID: 19793762
91. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Silje W Syversen, Espen A Haavardsholm, Pernille Bøyesen, Guro L Goll, Cecilie Okkenhaug, Per Ivar Gaarder, Désirée van der Heijde, and Tore K Kvien Ann Rheum Dis. 2010 May;69(5):845-50. PMID: 20233753
92. Alendronate reduces osteoclast precursors in osteoporosis. P D'Amelio, A Grimaldi, MA Cristofaro, M Ravazzoli, PA Molinatti, GP Pescarmona, and GC Isaia Osteoporos Int. 2010 Oct;21(10):1741-50. PMID: 19949772
93. Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors, Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after Viral Hepatitis. Jorge L. González-Calvin, Jose L. Mundi, Francisco J. Casado-Caballero, Ana C. Abadia, and Jose J. Martin-Ibañez J. Clin. Endocrinol. Metab., Dec 2009; 94: 4844 - 4850. PMID: 19897681
94. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency Aisha V. Sauer, Emanuela Mrak, Raisa Jofra Hernandez, Elena Zacchi, Francesco Cavani, Miriam Casiraghi, Eyal Grunebaum, Chaim M. Roifman, Maria C. Cervi, Alessandro Ambrosi, Filippo Carlucci, Maria Grazia Roncarolo, Anna Villa, Alessandro Rubinacci, and Alessandro Aiuti Blood, Oct 2009; 114, 3216-3226. PMID: 19633200
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 14/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
95. Non-association Between Polymorphisms of the Frizzled Receptor Genes and Bone Mineral Density in Postmenopausal Korean Women Jung Gu Kim, Hoon Kim, Byung Chul Jee, Chang Suk Suh, Young Min Choi, and Shin Yong Moon Journal of Korean Medical Science. 2009;24(3):443-447. PMCID: PMC2698190
96. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone Unni Syversen, Astrid K Stunes, Björn I Gustafsson, Karl J Obrant, Lars Nordsletten, Rolf Berge, Liv Thommesen, and Janne E Reseland BMC Endocrine Disorders. 2009;9:10. PMCID: PMC2678137
97. Increased serum OPG in atrophic nonunion shaft fractures Marchelli D, Piodi LP, Corradini C, Parravicini L, Verdoia C, Ulivieri FM. Traumatology : Official Journal of the Italian Society of Orthopaedics and Traumatology. 2009;10(2):55-58. PMCID: PMC2688591
98. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts Mizutani K, Sud S, Pienta KJ. Journal of cellular biochemistry. 2009;106(4):563-569. PMCID: PMC2776620
99. Bone Turnover and the Osteoprotegerin-RANKL Pathway in Tumor-Induced Osteomalacia: A Longitudinal Study of Five Cases. Domenico Rendina, Gianpaolo De Filippo, Libuse Tauchmanova, Luigi Insabato, Riccardo Muscariello, Fernando Gianfrancesco, Teresa Esposito, Michele Cioffi, Annamaria Colao, Pasquale Strazzullo, and Giuseppe Mossetti Calcif Tissue Int, Sep 2009; PMID: 19763378
100. A 246-km continuous running race causes significant changes in bone metabolism. Katharina Kerschan-Schindl, Markus Thalmann, Gottfried H Sodeck, Katerina Skenderi, Antonia L Matalas, Stephan Grampp, Christof Ebner, and Peter Pietschmann Bone. 2009 Dec;45(6):1079-83. PMID: 19665602
101. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Markus Rauchenzauner, Andrea Griesmacher, Tobias Tatarczyk, Edda Haberlandt, Alexander Strasak, Lothar-Bernd Zimmerhackl, Gerda Falkensammer, Gerhard Luef, and Wolfgang Hogler Dev Med Child Neurol. 2010 Mar;52(3):283-8. PMID: 19709134
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 15/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
102. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. L Jorgensen, A Vik, N Emaus, J Brox, J-B Hansen, E Mathiesen, and P Vestergaard Osteoporos Int. 2010 Jun;21(6):931-8. PMID: 19701599
103. The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget's Disease of Bone. S A Polyzos, A D Anastasilakis, Z Efstathiadou, M Kita, I Litsas, A Avramidis, G Arsos, E Moralidis, S Gerou, V Pavlidou, A Papatheodorou, and E Terpos Horm Metab Res. 2009 Nov;41(11):846-50. PMID:19670154
104. Interleukin-17, RANKL, and osteoprotegerin levels in gingival crevicular fluid from smoking and non-smoking patients with chronic periodontitis during initial periodontal treatment. N Buduneli, E Buduneli, and N Kutukculer J Periodontol, Aug 2009; 80(8): 1274-80. PMID: 19656027
105. Osteoclastogenesis in Children with 21-hydroxylase Deficiency on Long Term Glucocorticoid Therapy: The Role of RANKL/OPG Imbalance. Giacomina Brunetti, Silvia Colucci, Laura Piacente, Maria Ciccarelli, Lucia Giordani, Giovanni Carlo Del Vecchio, Massimo D'Amore, Livia Albanese, Luciano Cavallo, and Maria Grano J. Clin. Endocrinol. Metab., Jul 2009; 94:2269-2276. PMID: 19401376
106. The Clinical Significance of Serum Markers of Bone Turnover in NSCLC Patients: Surveillance, Management and Prognostic Implications. Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A, Syrigos KN. Anticancer Res, May 2009; 29: 1651 - 1657. PMID: 19443381
107. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Eleni M Karapanagiotou, Evangelos Terpos, Kalliopi D Dilana, Christina Alamara, Ioannis Gkiozos, Aris Polyzos, and Kostas N Syrigos Med Oncol. 2010 Jun;27(2):332-8. PMID: 19373566
Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia. S Honsawek, T Chaiwatanarat, P Vejchapipat, V Chongsrisawat, N Thawornsuk, and Y Poovorawan Pediatr Surg Int, Mar 2009; 25(3): 261-7. PMID: 19184056
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 16/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
108. Proinflammatory cytokines and receptor activator of nuclear factor kappaB- ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. N Turk, S Cukovic-Cavka, M Korsic, Z Turk, and B Vucelic Eur J Gastroenterol Hepatol, Feb 2009; 21(2): 159-66.
109. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. Nuria Guanabens, Anna Enjuanes, Luisa Alvarez, Pilar Peris, Llorenc Caballeria, M Jesus Martinez de Osaba, Dacia Cerda, Anna Monegal, Francesca Pons, and Albert Pares J Bone Miner Metab. 2009;27(3):347-54. PMID: 19229472
110. Effect of Anti-Infective Mechanical Therapy on Clinical Parameters and Cytokine Levels in Human Peri-Implant Diseases. Poliana Mendes Duarte, Adriana Cutrim de Mendonca, Maria Beatriz Braz Maximo, Vanessa Renata Santos, Marta Ferreira Bastos, and Francisco Humberto Nociti J Periodontol, Feb 2009; 80(2): 234-243. PMID: 19186963
111. Dysregulated RANK Ligand/RANK Axis in Hyperhomocysteinemic Subjects: Effect of Treatment With B-Vitamins. Marit S. Nenseter, Thor Ueland, Kjetil Retterstøl, Ellen Strøm, Lars Mørkrid, Sverre Landaas, Leiv Ose, Pål Aukrust, and Kirsten B. Holven Stroke, Jan 2009; 40: 241 – 247 PMID: 19008470
112. The HLA-B27 Transgenic Rat, a Model of Spondyloarthritis, Has Decreased Bone Mineral Density and Increased RANKL to Osteoprotegerin mRNA Ratio. Martina Rauner, Daniela Stupphann, Martin Haas, Ingrid Fert, Simon Glatigny, Wolfgang Sipos, Maxime Breban, and Peter Pietschmann J Rheumatol. 2009 Jan;36(1):120-6. PMID: 19040304
113. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? P Spelling, E Bonfa, VF Caparbo, and RM Pereira Scand J Rheumatol, Nov 2008; 37(6): 439-44. PMID: 18802807
114. Bone markers predict cardiovascular events in chronic kidney disease. A Fahrleitner-Pammer, J Herberth, SR Browning, B Obermayer-Pietsch, G Wirnsberger, H Holzer, H Dobnig, and HH Malluche J Bone Miner Res. 2008 Nov;23(11):1850-8. PMID: 18597636
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 17/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
115. Modifying RANKL/OPG mRNA Expression in Differentiating and Growing Human Primary Osteoblasts. M Giner, M J Montoya, M A Vazquez, M J Rios, R Moruno, M J Miranda, and R Perez-Cano Horm Metab Res. 2008 Dec;40(12):869-74. PMID: 18932123
116. Bone remodeling biomarkers of periodontal disease in saliva. BD Frodge, JL Ebersole, RJ Kryscio, MV Thomas, and CS Miller J Periodontol. 2008 Oct;79(10):1913-9. PMID: 18834246
117. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Héctor F Escobar-Morreale, José I Botella-Carretero, Ma Ángeles Martínez-García, Manuel Luque-Ramírez, Francisco Álvarez-Blasco, and José L San Millán Eur. J. Endocrinol., Sep 2008; 159: 225 - 232. PMID: 18579554
118. Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. K Kerschan-Schindl, J Wendlova, S Kudlacek, A Gleiss, W Woloszczuk, and P Pietschmann Exp Clin Endocrinol Diabetes, August 1, 2008; 116(8): 491-5. PMID: 18072013
119. α1β1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function Gendron S, Boisvert M, Chetoui N, Aoudjit F. Immunology. 2008;125(3):359-369. PMCID: PMC2669139
120. Does Osteoprotegerin or Receptor Activator of Nuclear Factor-κB Ligand Mediate the Association between Bone and Coronary Artery Calcification? Bakhireva LN, Laughlin GA, Bettencourt R, Barrett-Connor E. The Journal of Clinical Endocrinology and Metabolism. 2008;93(5):2009-2012. PMCID: PMC2386279
121. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells Tat SK, Pelletier J-P, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J. Clinical and experimental rheumatology. 2008;26(2):295-304. PMCID: PMC5247261
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 18/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
122. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappaB ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. A Pilichou, I Papassotiriou, K Michalakakou, S Fessatou, E Fandridis, G Papachristou, and E Terpos Clin Biochem, Jun 2008; 41(9): 746-9. PMID: 18355453
123. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year Genistein administration. Herbert Marini, Letteria Minutoli, Francesca Polito, Alessandra Bitto, Domenica Altavilla, Marco Atteritano, Agostino Gaudio, Susanna Mazzaferro, Alessia Frisina, Nicola Frisina, Carla Lubrano, Michele Bonaiuto, Rosario D’Anna, Maria Letizia Cannata, Francesco Corrado, Francesco Cancellieri, Marianna Faraci, Rolando Marini, Elena Bianca Adamo, Steven Wilson, and Francesco Squadrito JBMR, May 2008, Vol 23, No 5, 715-720 PMID: 18433304
124. Osteoclast inhibitory effects of vitamin k2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. M Morishita, M Nagashima, K Wauke, H Takahashi, and K Takenouchi J Rheumatol, Mar 2008; 35(3): 407-13. PMID: 18260178
125. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. P D'Amelio, A Grimaldi, S Di Bella, C Tamone, SZ Brianza, MG Ravazzoli, P Bernabei, MA Cristofaro, GP Pescarmona, and G Isaia J Bone Miner Res, Mar 2008; 23(3): 373-9. PMID: 17967134
126. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor- B ligand levels in women with established osteoporosis treated with teriparatide. Athanasios D Anastasilakis, Dimirtios G Goulis, Stergios A Polyzos, Spiridon Gerou, Vasiliki Pavlidou, George Koukoulis, and Avraam Avramidis Eur. J. Endocrinol., Mar 2008; 158: 411 - 415.
127. Does Osteoprotegerin or RANKL Mediate the Association Between Bone and Coronary Artery Calcification? Ludmila N. Bakhireva, Gail A. Laughlin, Ricki Bettencourt, and Elizabeth Barrett- Connor J. Clin. Endocrinol. Metab., Mar 2008; 10.1210/jc.2007-2624 PMCID: PMC2386279
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 19/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
128. Effects of compression force on fibroblast growth factor-2 and receptor activator of nuclear factor kappa B ligand production by periodontal ligament cells in vitro. R Nakajima, M Yamaguchi, T Kojima, M Takano, and K Kasai J Periodontal Res, Apr 2008; 43(2): 168-73. PMID: 18302618
129. Constitutional Thinness: Unusual Human Phenotype of Low Bone Quality. Bogdan Galusca, Mohamed Zouch, Natacha Germain, Cecile Bossu, Delphine Frere, Francois Lang, Marie-Helene Lafage-Proust, Thierry Thomas, Laurence Vico, and Bruno Estour J Clin Endocrinol Metab. January 2008, 93(1):110-117 PMID: 17956951
130. Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. RA Mangiafico, C Alagona, P Pennisi, N Parisi, M Mangiafico, F Purrello, and CE Fiore Osteoporos Int, Jan 2008; 19(1): 49-56. PMID: 17676381
131. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. RA Santiago, CA Silva, VF Caparbo, AM Sallum, and RM Pereira Scand J Rheumatol, Jan 2008; 37(1): 40-7. PMID: 18189194
132. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. HY Zhao, JM Liu, G Ning, YJ Zhao, Y Chen, LH Sun, LZ Zhang, MY Xu, and JL Chen Osteoporos Int, Feb 2008; 19(2): 221-6. PMID: 17703270
133. The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism Inaam A. Nakchbandi, Robert Lang, Barbara Kinder, and Karl L. Insogna J. Clin. Endocrinol. Metab., Dec 2007; 10.1210/jc.2007-1645. PMCID: PMC2266956
134. NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor Kubota, T., Hoshino, M., Aoki, K., Ohya, K., Komano, Y., Nanki, T., Nobuyuki M., Umezawa, K. Arthritis Research & Therapy, 9(5), R97. PMCID: PMC2212584
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 20/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
135. Serum Osteoprotegerin Concentration with Strontium Ranelate Treatment for Postmenopausal Osteoporosis: An Open, Prospective Study Ertorer ME, Bakiner O, Anaforoglu I, Sezgin N, Demirag NG, Tutuncu NB. Current Therapeutic Research, Clinical and Experimental. 2007;68(4):217-225. PMCID: PMC3967269
136. The Sex-Specific Association of Serum OPG and RANKL with Bone Mineral Density in Older Adults: The Rancho Bernardo Study. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. European journal of endocrinology / European Federation of Endocrine Societies. 2007;156(5):555-562. PMCID: PMC2642656
137. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients Andersson MK, Lundberg P, Ohlin A, et al. Arthritis Research & Therapy. 2007;9(1):R18. doi:10.1186/ar2127. PMCID: PMC1860076
138. Bone structure and metabolism in a rodent model of male senile osteoporosis. P Pietschmann, M Skalicky, M Kneissel, M Rauner, G Hofbauer, D Stupphann, and A Viidik Exp Gerontol, Nov 2007; 42(11): 1099-108.
139. Genetic background influences fluoride's effects on osteoclastogenesis. D Yan, A Gurumurthy, M Wright, TW Pfeiler, EG Loboa, and ET Everett Bone, Dec 2007; 41(6): 1036-44. PMCID: PMC2238641
140. Elevated soluble receptor activator of nuclear factor-kappaB ligand and reduced bone mineral density in patients with adolescent idiopathic scoliosis. KT Suh, SS Lee, SH Hwang, SJ Kim, and JS Lee Eur Spine J, Oct 2007; 16(10): 1563-9. PMCID: PMC2078303
141. Expression of cathepsin-K in gingival crevicular fluid of patients with periodontitis. M Mogi and J Otogoto Arch Oral Biol, Sep 2007; 52(9): 894-8.
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 21/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
142. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Pal Miheller, Gyorgyi Müzes, Karoly Racz, Anna Blazovits, Peter Lakatos, Laszlo Herszenyi, and Zsolt Tulassay Inflamm Bowel Dis. 2007 Nov;13(11):1379-84. PMID: 17663430
143. Soluble Receptor Activator of Nuclear Factor-B Ligand and Risk for Cardiovascular Disease. Stefan Kiechl, Georg Schett, Judith Schwaiger, Klaus Seppi, Paula Eder, Georg Egger, Peter Santer, Agnes Mayr, Qingbo Xu, and Johann Willeit Circulation, Jul 2007; 116: 385 - 391.
144. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. V Goranova-Marinova, S Goranov, P Pavlov, and T Tzvetkova Haematologica, Jul 2007; 92(7): 1000-1. PMID: 17606458
145. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. MP Whyte, PN Singhellakis, MB Petersen, M Davies, WG Totty, and S Mumm J Bone Miner Res, Jun 2007; 22(6): 938-46. PMID: 17352649
146. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects. RA Mangiafico, G Malaponte, P Pennisi, G Li Volti, G Trovato, M Mangiafico, Y Bevelacqua, F Mazza, and CE Fiore J Intern Med, Jun 2007; 261(6): 587-96. PMID: 17547714
147. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor B legend with bone mineral density in older adults: the Rancho Bernardo Study. Anna Stern, Gail A Laughlin, Jaclyn Bergstrom, and Elizabeth Barrett-Connor Eur. J. Endocrinol., May 2007; 156: 555 - 562. PMCID: PMC2642656
148. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. S Mora, I Zamproni, L Cafarelli, V Giacomet, P Erba, G Zuccotti, and A Vigano AIDS, May 2007; 21(9): 1129-35. PMID: 17502723
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 22/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
149. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. A Monegal, M Navasa, P Peris, L Alvarez, F Pons, J Rodes, and N Guanabens Liver Int, May 2007; 27(4): 492-7. PMID: 17403189
150. The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis. N Morabito, GT Russo, A Gaudio, A Lasco, A Catalano, E Morini, F Franchina, D Maisano, M La Rosa, M Plota, A Crifo, A Meo, and N Frisina Bone, Jun 2007; 40(6): 1588-94. PMID: 17412659
151. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. T. Lequerré, F. Jouen, M. Brazier, S. Clayssens, N. Klemmer, J.-F. Ménard, O. Mejjad, A. Daragon, F. Tron, X. Le Loët, and O. Vittecoq Rheumatology, Mar 2007; 46: 446 - 453. PMID: 16899502
152. RANKL: Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Kelly A Rouster-Stevens, Craig B Langman, Heather E Price, Roopa Seshadri, Richard M Shore, Kathy Abbott, and Lauren M Pachman Arthritis Rheum, Feb 2007; 56(3): 977-983. PMID: 17328075
153. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. NG Angelopoulos, A Goula, E Katounda, G Rombopoulos, V Kaltzidou, D Kaltsas, S Malaktari, V Athanasiou, and G Tolis J Bone Miner Metab, Jan 2007; 25(1): 60-7. PMID: 17187195
154. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G. Am J Pathol. 2006 Dec;169(6):2236-44. PMCID: PMC1762477
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 23/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
155. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor- kappaB ligand concentrations and normalises indices of bone remodeling in patients with relapsed multiple myeloma. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Br J Haematol. 2006 Dec;135(5):688-92. PMID: 17107351
156. IL-7 Up-Regulates TNF-α-Dependent Osteoclastogenesis in Patients Affected by Solid Tumor Ilaria Roato, Giacomina Brunetti, Eva Gorassini, Maria Grano, Silvia Colucci, Lisa Bonello, Lucio Buffoni, Roberto Manfredi, Enrico Ruffini, Davide Ottaviani, Libero Ciuffreda, Antonio Mussa, and Riccardo Ferracini PLoS ONE. 2006;1(1):e124. PMCID: PMC1762428
157. An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction Paola Secchiero, Federica Corallini, Assunta Pandolfi, Agostino Consoli, Riccardo Candido, Bruno Fabris, Claudio Celeghini, Silvano Capitani, and Giorgio Zauli The American Journal of Pathology. 2006;169(6):2236-2244. PMCID: PMC1762477
158. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. British Journal of Cancer. 2006;95(4):506-514. PMCID: PMC2360666
159. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati, A, De Paola V, Valleggi F, Nuti R. Bone. 2007 Feb;40(2):457-63. Epub 2006 Sep 18. PMID: 16979395 160. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. Mazziotti G, Amato G, Sorvillo F, Piscopo M, Rizzo MR, Lalli E, Iride L, Ciuffi M, Molinari AM, Paolisso G, Carella C. Eur J Endocrinol. 2006 Mar;154(3):373-7. PMID: 19346738
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 24/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
161. Association between phosphate removal and markers of bone turnover in haemodialysis patients. Albalate M, de la Piedra C, Fernandez C, Lefort M, Santana H, Hernando P, Hernandez J, Caramelo C. Nephrol Dial Transplant. 2006 Jun;21(6):1626-32. PMID: 16490746
162. Are activated T cells regulators of bone metabolism in children with Crohn disease? FA Sylvester, PM Davis, N Wyzga, JS Hyams, and T Lerer J Pediatr, Apr 2006; 148(4): 461-6 PMID: 16647405
163. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S. Pediatr Blood Cancer. 2006 Aug;47(2):194-9. PMID: 16358318
164. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. Zojer N, Brenner K, Beke D, Kudlacek S, Hawa G, Woloszczuk W, Hofbauer LC, Pecherstorfer M. Anticancer Res. 2005 Sep-Oct;25(5):3607-12. PMID: 16101188.
165. Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. Chan MH, Wong K, Chan IH, Luo YF, Tam S, Lam CW. Pathology 37:1, 2005, 51 – 55 PMID: 15875734
166. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM. Rheumatology 2005 44(12):1503-1506 PMID: 16219645
167. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL. Bone 2005 Apr;36(4):727-35 PMID: 15781001
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 25/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
168. Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Circulation. 2005;111:2461-2468 PMID: 15883214
169. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H. Gut 2005 54: 479-487 PMCID: PMC1774465
170. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Zh, Sun LH, Xu MY, Chen JL. Calcif Tissue Int 2005 Jan;76(1):1-6 PMID: 15455183.
171. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. Maïmoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E, Ohanna F, Cristol JP, Rossi M, Leroux JL. Calcif Tissue Int 2005 Jun;76(6):404-11 PMID: 15812577
172. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J, Pons-Romero F. Liver International 2005 25:2 305 PMID: 15780054
173. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D Clin Endocrinol (Oxf). 2004 Jan;60(1):87-91. PMID: 14678293
174. Soluble RANKL and Risk of Nontraumatic Fracture. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J. JAMA.2004; 291:2703 PMID: 14996780
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 26/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
175. Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients FRANCHIMONT, N., REENAERS, C., LAMBERT, C., BELAICHE, J., BOURS, V., MALAISE, M., DELVENNE P., LOUIS, E. Clinical and Experimental Immunology, 2004 : 138(3), 491–498. PMCID: PMC1809233
176. Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of Coronary Artery Disease in Men. Schoppet M, Schaefer JR, Hofbauer LC. Circulation. 2003 Mar 25;107(11):e76; PMID: 12654623
177. Serum osteoprotegerin but not receptor activator of NF-{kappa}B ligand correlates with Larsen score in rheumatoid arthritis. Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A. Ann Rheum Dis 2004 63: 216-217 PMCID: PMC1754876
178. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, Delvenne P, Louis E. Clin Exp Immunol 2004 Dec;138(3):491-8 PMCID: PMC1809233
179. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1ß and tumour necrosis factor. Dai S, Nishioka K, Yudoh K. Annals of the Rheumatic Diseases 2004;63:1379-1386 PMCID: PMC1754791
180. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, Fiore CE. Osteoporosis International 2004, 15:5, 389 – 395 PMID: 14661073
181. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M. Clinical Endocrinology 60:2 2004, p214 PMID: 14725683
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 27/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
182. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R, Liso A, Capalbo S, Liso V, Zallone A, Grano M. Blood, 104:12, 2004. 3722-3730 PMID: 15308561
183. OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis, osteoarthritis and spondylarthropathy. Krystufkova O, Niederlova J, Senolt V, Hladikova M, Ruzickova S, Vencovsky J. Arthritis Res Ther 2003, 5(Suppl 1):102 PMCID: PMC2833669
184. Receptor Activator of Nuclear Factor kß Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis. Eva Grimaud, Luc Soubigou, Séverine Couillaud, Patrick Coipeau, Anne Moreau, Norbert Passuti, François Gouin, Françoise Redini, and Dominique Heymann American Journal of Pathology, Vol. 163, No. 5, 2003 PMCID: PMC1892410
185. Soluble receptor activator of nuclear factor kB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A. Blood. 2003 Aug 1;102(3):1064-9. PMID: 12689925.
186. Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S, Woloszczuk W. Clin Lab. 2003;49(9-10):461-3 PMID: 14572201
187. OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis, osteoarthritis and spondylarthropathy Krystufkova O, Niederlova J, Senolt V, Hladikova M, Ruzickova S, Vencovsky J. Arthritis Research & Therapy. 2003;5(Suppl 1):102. PMCID: PMC2833669
188. Unusual Association between Increased Bone Resorption and Presence of Paroxysmal Nocturnal Hemoglobinuria Phenotype in Multiple Myeloma. Terpos E, Samarkos M, Meletis C, Apostolidou E, Tsironi M, Korovesis K, Mavrogianni D, Viniou N, Meletis J. International Journal of Hematology 78: 4, 2003, 344 - 348 PMID: 14686493
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 28/29
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA Last update March 2018
189. Effect of Anticoagulants and Storage Temperature on the Stability of Receptor Activator for Nuclear Factor-B Ligand and Osteoprotegerin in Plasma and Serum. Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Clin Chem 2003 49: 2083-2085. PMID: 11311219
190. Osteoprotegerin and sRANKL serum levels in multiple myeloma patients. Barbara Kruk, Maria Kraj, Piotr Centkowski, Urszula Sokołowska Centr Eur J Immunol 2002 ; 27 (4) : 129-135
191. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V. Blood 2002 Dec 15;100(13):4615-21 PMID: 12393684
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 29/29